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Abstract 
Introduction: Genetic profile studies of breast cancer identified a number of biologically different subtypes. These genetic subtypes are 
often surrogated by oestrogen receptors (ERs), progesterone receptors (PR) and HER2 status as measured by immunohistochemistry 
(IHC). Triple negative (TN) subtype is recognized to have high-risk features and poor outcome. Over-expression of the HER2 is also 
recognized as poor outcome marker. The characteristics and outcome of HER2 positive tumours (irrespective of hormonal status) (HER2 
HR+/-) identified by IHC have not addressed in the era of surrogate genetic subtyping. Therefore, we retrospectively compared the risk 
features and clinical outcome of patients with TN against these with HER2 HR+/- tumours. 
Patients and Methods: Forty patients with HER2 HR+/- tumours were matched for age and stage to 40 patients with TN tumours. 
Clinical and pathological data were collected retrospectively. All patients were managed in a single institution. 
Results: Tumour grade and stage and rate of pathologically involved lymph nodes were similar in both groups. There was a trend of 
more lymphovascular invasion in HER2 HR+/- than TN patients (40% vs. 27.5%. p=0.07). Relapse and death rates were not statistically 
different (p=0.469 and p=1.0, respectively). Median relapse free survival was 38 months for TN and not reached for HER2 HR+/- patients 
(Log rank; p=0.757). Median overall survival was not reached in both groups. Multivariate analysis did not identify TN or HER2 HR+/- 
status to have any differential impact on RFS.  
Conclusion: HER2 HR+/- tumours exhibit high risk, presenting features and relatively poor clinical outcome possibly not very different 
from the increasingly recognized TN tumour. 
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Introduction 
The class discovery expression profile studies pioneered by the 
Stanford group [1, 2] have demonstrated that the morphological 
heterogeneity of breast cancer can be recapitulated and 
systematically classified at the transcriptomic level. These 
studies have shown that the expression profiles of breast 
cancer display a systematic variation and allow classification of 
breast cancer into five main groups, two of them ER+ 
(oestrogen receptor positive)[luminal A and B] and three ER- 
(oestrogen receptor negative) groups [normal breast-like, 
ERBB2 (also known as HER2) and ‘basal-like’][1, 3]. 
In these, and in subsequent studies, it has been shown that the 
basal-like group is enriched for tumours that lack expression of 
hormone receptors and of HER2 and has a more aggressive 
clinical behaviour,  a distinctive metastatic pattern [4, 5] and a 
poor prognosis despite responding to conventional neoadjuvant 
and adjuvant chemotherapy regimens[6, 7]. 
The basal-like subtype accounts for about 15% of breast cancer 
cases. Because basal-like breast cancers are ER-, PR- 
(progesterone receptor negative) and HER2 negative, they are 
sometimes called ‘triple negative’, (TN). Some investigators 
have concluded that TN breast cancer is synonymous with 
basal-like breast cancer although it should be noted that only 
about 85% of triple-negative phenotypic breast cancers are 
deemed to be basal-like when tested by appropriate 
immunohistochemical means [8]. 
Over-expression of the HER 2 oncoprotein irrespective of 
hormone receptor status (HER2 HR+/-) is a well-known adverse 
prognostic factor associated with poor relapse free (RFS) and 
over all survival (OS) in breast cancer [9]. 
A number of studies investigated the characteristics of TN 
tumours in comparison with a cohort of mix of other subtypes 
[10, 11]. However, there are no data in the literature comparing 
TN and HER2 HR+/- groups, two subtypes with seemingly 
poorest outcome. 
Gene expression analysis has not become a standard test in 
daily clinical management of breast cancer. However, 
physicians are increasingly using ER, PR and HER2 status to 
try and predict tumour behaviour and clinical outcome. The five 
identified subtypes based on receptors status do not include a 
category of HER2 HR+/-. About 20%–25% of patients fall in this
group. In this report, we investigate the clinical characteristics 
and outcome of HER2 HR+/- and compare it to that of age and 
stage matched TN patients in a cohort of patients with early 
breast cancer. 
 
Patients and methods 
Patients and data source 
Forty patients with HER2 HR+/- tumours were identified. 1:1 
matching for age and stage was performed to identify 40 
patients with TN tumours. All patients attended King Faisal 
Specialist Hospital and Research Centre-Jeddah, Kingdom of 
Saudi Arabia. Patients were identified from the hospital 
oncology electronic database. 
All patients received their management at our facility from 
January 2002 to December 2007. Initial evaluation included 
clinical examination, mammography and breast ultrasound. 
Computed tomography of chest, bone scan and breast 
magnetic resonance imaging were performed if indicated. 
Clinical data were collected from the oncology database, 
electronic results system and supplemented by retrospective 
review of patients’ medical records. The hospital’s institutional 
review board (ethical committee) approved the project. 
 
Immunohistochemistry analysis 
Immunohistochemical staining was carried out using standard 
streptavidin-biotin peroxidase method on 3- to 5-mm-thick tissue 
sections. Staining was performed with antibodies raised against 
the following markers: ER, PR and HER 2. ER and PR status 
were recorded according to the pathologist’s interpretation of 
the assays. ER and PR were considered negative if 
immunoperoxidase staining of tumour cell nuclei is <5%. A 
negative HER-2 expression using HercepTest (Dako, Glostrup, 
Denmark) was defined as no membranous staining (negative) 
or those that either had some staining in <10% of tumour cells 
or had weak-to-moderate staining (1+). Those who had 
moderate staining in >10% of cells (2+) were further evaluated 
by fluorescence in situ hybridisation (FISH) for gene 
amplification. FISH is scored on a quantitative scale with less 
than two copies of the HER-2 gene classified as negative. 
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Table 1: Patients’ characteristics and treatment 
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Table 2: Breast cancer outcome: Rates of relapse and death 
Statistical analysis 
Demographic, clinical, pathological and treatment variables in 
both groups were compared using Chi-squared test for 
categorical variables. T test was used to compare means. RFS 
was calculated from date of diagnosis to date of relapse or last 
follow-up. OS was calculated from date of diagnosis to date of 
death or last follow-up. RFS and OS were computed using 
survival tables and Kaplan Meier method. Log rank test was 
used to test the difference between both groups. Cox regression 
model was used to calculate hazards ratio and to adjust for 
potential prognostic variables 
 
Results 
Table 1 illustrates patients’ characteristics and treatment for the 
whole cohort and for each group. Patients’ age and tumour 
stage in both groups were identical due to the matched design 
of the study. Tumour grade was similar in both groups. LVI was 
reported more often in HER2 HR+/- than TN patients (40% vs. 
27.5%, p=0.07). Fifty percent of HER2 HR+/- patients 
were ER+, 45% were PR+, 45% were positive for both 
receptors and 50% were HR+ (positive ER and/or PR). 
Treatments (type of surgery, neoadjuvant chemotherapy, 
adjuvant chemotherapy and adjuvant radiotherapy) were similar 
in both groups. The difference in hormone receptor status and 
adjuvant hormonal therapies reflects the nature of patients in 
the study. 
After a median follow-up of 21.5 months, 35% and 27% 
relapsed and 7.5% and 7.5% died in TN and HER2 HR+/- 
groups, respectively (p=not significant) (Table 2). Median RFS 
was 38 months for TN and not reached for HER2 HR+/- patients 
(p=0.043). Median OS was not reached in both groups (Table 
2). 
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Figure 1: Relapse free survival of TN and HER2 HR+/- groups (n=80).
At 3 years, RFS was 55% and 70% and OS was 81% and 93% 
in TN and HER2 HR+/- groups, respectively (Figures 1 and 2). 
In HER2 HR+/- group, 20 patients had HR+ disease, 6/20 (30%) 
relapsed. Twenty patients had HR- disease, 5/20 (25%) 
relapsed. The difference in relapse rate between HR+ and HR- 
subgroups was not statistically significant (p=0.723). The 
median RFS was not reached in these subgroups (p=0.757). 
On Cox regression multivariate analysis, stage, number of 
pathologically involved lymph nodes, grade, TN and HER2 
HR+/- were found to have no significance impact on RFS. 
 
Discussion 
Tumours that over-express HER-2 can be ER- or ER+. 
Oncologists are well aware that HER-2 over-expression is an 
independent poor prognostic factor (9). The incorporation of 
Trastuzumab in the adjuvant and palliative treatments improved 
the outcome [12, 13]. 
The TN tumours lack the expression of all three routinely tested 
receptors (ER, PR and HER-2) and are being increasingly 
recognized among oncologists as another poor prognostic 
group.  
Both TN and HER2 HR+/- tumours present with high-risk 
features that include higher stage, high-pathological grade and 
involvement of lymph nodes, and at the same time both share a 
poor outcome. 
In this report, we study the tumour features and outcome of 
these two seemingly poorest outcome groups after matching for 
two independent prognostic factors, that is age and stage. 
The mean age of our patients is relatively young 45 (42–49) 
years. It is possible that part of this is artificial due to matching 
process. However, other factors may explain this finding; (I) 
patients with TN tumours present at a younger age than other 
subtypes [11], (II) the frequency of HER-2 over-expression 
decreases with increasing age at diagnosis [14] although this 
may not be a unanimous finding as some data show HER-2 
over-expression not significantly different in women <35 and 
>=35 years [15], (III) women in Saudi Arabia present with breast 
cancer at younger age. In the 2004 Saudi cancer incidence 
report, 44% and 59% of patients were <45 and <50 years, 
respectively (16). In a retrospective review of 780 patients who  
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Figure 2: Overall survival of TN and HER2 HR+/- groups (n=80).
received chemotherapy in Saudi Arabia, 64% of patients were 
<50 years and 62% were pre-menopausal [3]. 
HER-2 tumours are more likely to be ER- or express lower 
levels of ER than if they are Her-2 negative [14, 17]. However, 
the association between ER, PR and HER-2 over-expression 
varies with age. The hormone receptors are not an independent 
predictor for HER-2 expression in young women while they are 
in elder patients (>45 years) (18). Fifty percent of our patients 
were HR+. This is generally accepted representation for this 
group of patients. In the HERA phase III international study, 
50.8% and 50.1% of HER-2 tumours were HR+ in the 1-year 
trastuzumab and the observation arms, respectively. This 
suggests that despite small sample size and selection for 
matching our sample represents the true characteristics and 
features of this group of tumours [12]. The mean age of our 
patients was 45 years, and all were younger than 50 years. This 
may have had an impact on the loss of HR-predominance. 
More than half of patients in each group had pathologically 
involved lymph nodes (TN: 61.5% and HER2 HR+/-: 53.8% P 
0.492). This high-risk feature is present and not statistically 
different in both groups of our patients. There are conflicting 
results on the prevalence of lymph node metastasis at the time 
of diagnosis in patients with TN cancers, whereas in one study 
there was a higher prevalence of lymph node metastasis in TN 
compared with non-TN controls (54.4% vs. 45.6% p=0.02) [11]; 
others have found an opposite association (24.1% vs. 42.1% 
p=0.01) (19). It is worth mentioning that the controls in these 
two comparisons were unselected patients with breast cancer 
that contained a mix of all subtypes. The lack of significant 
difference in rate of involved lymph nodes in our patients 
indicates that both groups likely share high-risk features. 
However, this may be at least partly explained by the design of 
matching for stage. 87.5% of our patients in each group had 
stage II or III. This mostly indicates N1 or N2 in TNM 
classification (although some patients with stage II can be N0 in 
AJCC staging). In a closer look at the numbers of involved 
lymph nodes, we found that in TN and HER2 HR+/-, 8/39 
(20.5%) and 17/39 (43.6%) had four or more involved lymph 
nodes while 16/39 (40%) and 4/39 (10.3%) had one to three 
involved lymph nodes, respectively. This suggests that HER2 
HR+/- may present with higher risk feature than TN when 
considering number of involved lymph nodes. 
Lymphovascular invasion (LVI) and high pathological grade are 
features frequently reported in TN tumours. In a previous work 
our group compared features of TN and Luminal A tumours. 
The group found more LVI and grade III features in TN than in 
luminal A tumours (p=0.03 and 0.007), respectively. These 
findings were also reported by a Canadian group comparing TN 
and other pathological types in a cohort of 1601 patients [11]. In 
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the current study, we found a trend of more LVI in HER2 HR+/- 
than in TN; 40% and 27.5% (p=0.07). This did not reach 
statistical significance probably due to relatively small sample 
size and lack of LVI data in 32.5% and 22.5% of patients. 
Pathological Grade III was similar in both groups. This points to 
the possibility that HER2 HR+/- also present with poor 
prognostic factors similar to or may be worse than TN tumours. 
Despite shorter median duration of follow-up for the TN group 
(15 vs. 29.6 months), the rate of relapse was 35% in the TN 
group and 27.5% in the HER2 HR+/- (p=0.469). It is logical to 
assume more relapses will have occurred if TN group were 
followed up longer. However, it is possible that longer follow-up 
may not yield significantly more relapses as it is well 
documented that peak risk of recurrence in TN tumours occurs 
relatively early between the first and third years [11, 19]. This 
phenomenon of early recurrence with in 3 years is also 
supported by our finding of the inferior 3-year RFS of TN group 
compared to HER2 HR+/- (55% vs. not reached; p=0.043).  
Adjuvant trastuzumab became a standard adjuvant therapy for 
women with intermediate and high-risk HER2 breast cancer 
tumours in December 2005 at our institution. For this reason, 
only 15/40 (37.5%) patients received adjuvant trastuzumab. The 
other 25 patients did not receive adjuvant trastuzumab either 
due to diagnosis before this era, presence of medical 
contraindication or lack of other intermediate and/or high-risk 
features. It is reasonable to suggest that in this day and time 
more patients will receive adjuvant trastuzumab, and this will 
impact favourably at PFS for this group. 
On multivariate analysis, there was no significance impact on 
TN and HER2 HR+/- status on RFS, suggesting that these two 
factors per se impose similar outcome. 
There were only three deaths in each group. Three year OS 
was 81% and 93% in TN and HER2 HR+/- groups, respectively 
(p=0.35). The lack of difference in survival can be due to: (I) 
short duration of follow-up. (II) Patients in TN group who 
relapsed toward the end of 3 years may have had good 
response to salvage chemotherapy and thus did not translate to 
early death. It is well reported that TN tumours respond well to 
neoadjuvant chemotherapy [6]. However, data on outcome in 
response to chemotherapy after recurrence are sparse and
there remains considerable heterogeneity in individual 
outcomes [20]. (III) Probable true similar survival outcome in 
these two groups, namely TN and HER2 HR+/-. (IV) Only 37.5% 
of HER2 HR+/- patients received adjuvant trastuzumab. 
More accurate information on recurrence and mortality will be 
obtained with longer follow-up of our cohort and with multi-
institutional approach to study larger number of patients. 
Targeting patients treated in the era of adjuvant trastuzumab in 
future studies will make results more clinically relevant to 
current practice. 
It is worth reminding here that there are other subtypes of 
breast cancer identified on genetic profiling. The luminal 
subtype C is further distinguished from luminal subtypes A and 
B by the high expression of a novel set of genes whose 
coordinated function is unknown, which is a feature they share 
with the basal-like and ERBB2 subtypes [1]. The luminal 
subtype B and C tumours might represent a clinically distinct 
group with a different and poor disease course, in particular with 
respect to relapse. Luminal subtype C is associated with the 
worst outcome of the three luminal subtypes. The potential 
clinical significance of this molecular subtype is highlighted by 
the similarities in expression of some of the genes that are 
characteristic of the ER-tumours in the basal-like and ERBB2 
subtypes, which suggests that the high level of expression of 
this set of genes is associated with poor disease outcomes.   
Based on the above work by Sørlie T et al [1], it is possible that 
proportion of HER2 HR+/- patients in our series belong to the 
luminal C subtype. This may explain their high-risk features at 
presentation and a relatively high overall relapse rate (27.5%). 
Further genetic profile work is needed to classify HER2 HR+/- 
tumours. 
 
Conclusion  
At the current era of surrogacy of genetic profile and routine 
pathological feature of breast cancer, we identify HER2 HR+/- 
tumours as a subtype with high risk, presenting features and 
relatively poor clinical outcome possibly not very different from 
the increasingly recognized TN tumours. 
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